A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib

Publisher： Karger

E-ISSN： 1662-6575|7|3|628-632

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.7, Iss.3, 2014-09, pp. : 628-632

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 83, Iss. 5, 2012-09 ,pp. : 248-256

Karger

Access to resources Recommend Favorite

EML4-ALK in non-small-cell lung cancer: the breathtaking progress from benchtop to Phase III clinical trial

By Ku Geoffrey Y   Lima Jopes Jr Gilberto de  

Therapy, Vol. 8, Iss. 1, 2011-01 ,pp. : 55-61

Future Medicine

Access to resources Recommend Favorite

Epidemiology of EML4–ALK translocations in a small, German non-small-cell lung cancer patient cohort

By Schildgen Verena   Lochi Vincenza   Lüsebrink Jessica   Brockmann Michael   Schildgen Oliver  

Personalized Medicine, Vol. 9, Iss. 8, 2012-11 ,pp. : 801-803

Future Medicine

Access to resources Recommend Favorite

Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 664-674

John Wiley & Sons Inc

Access to resources Recommend Favorite

Experience in Integrating ALK Testing and Crizotinib into the Routine Treatment of Patients with Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-04 ,pp. : 342-347

Karger

Access to resources Recommend Favorite